IRIS
MERLINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.279
AS - Asia 10.995
EU - Europa 8.915
SA - Sud America 1.261
AF - Africa 148
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 15
AN - Antartide 1
Totale 35.640
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.006
CN - Cina 5.948
SG - Singapore 2.661
IE - Irlanda 2.548
HK - Hong Kong 1.303
RU - Federazione Russa 1.127
FI - Finlandia 1.102
UA - Ucraina 1.066
BR - Brasile 1.047
DE - Germania 984
IT - Italia 599
SE - Svezia 481
VN - Vietnam 422
GB - Regno Unito 408
FR - Francia 161
CA - Canada 160
IN - India 147
JP - Giappone 80
AR - Argentina 77
MX - Messico 75
BE - Belgio 70
BD - Bangladesh 68
PL - Polonia 66
NL - Olanda 55
TR - Turchia 55
ZA - Sudafrica 55
AT - Austria 48
ES - Italia 47
IQ - Iraq 37
ID - Indonesia 30
IR - Iran 28
LT - Lituania 28
PK - Pakistan 28
CZ - Repubblica Ceca 27
EC - Ecuador 26
VE - Venezuela 24
CO - Colombia 21
AE - Emirati Arabi Uniti 19
PY - Paraguay 19
AU - Australia 18
MA - Marocco 17
CL - Cile 16
MU - Mauritius 16
SA - Arabia Saudita 16
UZ - Uzbekistan 16
KE - Kenya 15
AZ - Azerbaigian 13
KR - Corea 13
PE - Perù 13
GR - Grecia 12
IL - Israele 11
KZ - Kazakistan 11
PH - Filippine 11
UY - Uruguay 11
EG - Egitto 10
EU - Europa 10
JM - Giamaica 10
RO - Romania 10
JO - Giordania 9
LV - Lettonia 9
TH - Thailandia 9
BG - Bulgaria 8
KG - Kirghizistan 8
MY - Malesia 8
DK - Danimarca 7
NP - Nepal 7
NZ - Nuova Zelanda 7
PA - Panama 7
PT - Portogallo 7
BO - Bolivia 6
CH - Svizzera 6
LB - Libano 6
AL - Albania 5
AM - Armenia 5
DZ - Algeria 5
EE - Estonia 5
MD - Moldavia 5
BB - Barbados 4
HU - Ungheria 4
LK - Sri Lanka 4
NG - Nigeria 4
TN - Tunisia 4
BN - Brunei Darussalam 3
ET - Etiopia 3
HN - Honduras 3
IS - Islanda 3
KH - Cambogia 3
MK - Macedonia 3
ML - Mali 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GA - Gabon 2
IM - Isola di Man 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 35.597
Salva come PNG Salva come JPEG
Città #
Dublin 2.541
Chandler 2.425
Jacksonville 1.523
Nanjing 1.318
Hong Kong 1.295
Dallas 1.197
Singapore 1.188
Ashburn 1.105
Beijing 983
Boardman 695
Nanchang 564
Princeton 522
Lawrence 488
Wilmington 471
Shenyang 403
Medford 395
Hebei 380
Helsinki 345
Changsha 343
Los Angeles 341
Jiaxing 304
Ann Arbor 276
Tianjin 246
Hangzhou 223
Buffalo 210
New York 192
Redondo Beach 191
Moscow 185
Munich 179
Ho Chi Minh City 161
Shanghai 156
Milan 128
Pavia 125
Woodbridge 111
Norwalk 100
São Paulo 93
Hanoi 91
Turku 74
Chicago 71
Brussels 67
Tokyo 67
Toronto 67
Piscataway 62
Verona 61
Fairfield 60
Seattle 56
Santa Clara 55
Warsaw 55
Brooklyn 53
London 51
The Dalles 48
Zhengzhou 47
Guangzhou 46
Ningbo 44
Washington 43
Des Moines 42
Johannesburg 42
Falkenstein 41
Stockholm 40
Chennai 39
Nuremberg 39
San Francisco 39
Denver 38
Montreal 37
Rio de Janeiro 34
Atlanta 33
Houston 33
Boston 31
Frankfurt am Main 31
Mexico City 31
Jinan 30
Phoenix 29
Pune 29
Kunming 27
Orem 27
Belo Horizonte 25
Brasília 23
Manchester 22
Poplar 22
Amsterdam 20
Ankara 20
Da Nang 20
Vienna 20
Charlotte 19
Council Bluffs 19
Taizhou 19
Curitiba 18
Dhaka 18
Secaucus 18
Auburn Hills 17
Lanzhou 17
Baghdad 16
Falls Church 16
Haiphong 16
Induno Olona 16
Porto Alegre 16
Rome 16
Biên Hòa 15
Columbus 15
Fuzhou 15
Totale 23.670
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 167
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 142
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 130
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 129
Fibrillazione atriale e amiloidosi cardiaca AL: un connubio intrigante 128
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 126
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 125
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 122
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 119
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 118
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study 115
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 112
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils:inhibition of amyloidogenesis. 112
Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. 112
AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies 111
Amyloid typing: immunoelectron microscopy 111
Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis 111
4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. 110
Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. 110
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 110
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 109
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 109
AMYLOIDOSIS AL 108
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 108
Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. 107
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. 107
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 107
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 107
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 107
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 107
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 107
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 107
International prognostic scoring system for Waldenstrom macroglobulinemia 106
Heavy chain disease can be detected by capillary zone electrophoresis. 106
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 106
Acute phase proteins and prognosis in multiple myeloma. 106
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 105
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 105
Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. 105
A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis 105
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 105
A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. 104
Bone marrow amyloidosis. 104
A patient with AL amyloidosis with negative free light chain results 104
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 104
“Separation and quantification of two beta2-microglobulin isoforms”. 103
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 103
Characterization of the two unique human anti-flavin monoclonal immunoglobulins. 103
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 103
Hereditary amyloidosis 102
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 101
AMICA: an electronic patient record specifically designed for an amyloidosis network 101
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 101
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 100
Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. 100
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 99
Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils 99
Waldenstrom macroglobulinemia 99
Structural characterization of kappa II Inc, a new amyloid immunoglobulin 98
Clotting alterations in primary systemic amyloidosis. 98
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 98
4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid 98
Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. 97
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 97
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 97
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 96
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 96
Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. 95
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 95
Biochemical markers in early diagnosis and management of systemic amyloidoses 95
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 95
Metodo per la separazione e la quantificazione di due conformazioni di beta-2-microglobulina in equilibrio dinamico 95
Diagnostic performance of triggering receptor expressed on myeloid cells-1 and CD64 index as markers of sepsis in preterm newborns 95
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 94
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 94
Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients 94
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 94
Comparison of three strategies for myocardial protection during coronary artery bypass graft surgery based on markers of cardiac damage. 93
A plea to overcome th concept of "staging" and related inadequacy in multiple myeloma. 93
Holter monitoring in AL amyloidosis: prognostic implications. 93
Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial 93
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 93
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 92
Structural features of two monoclonal cryocrystalglobulins causing a rheumatic syndrome with vasculitis. 91
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 91
Valore prognostico della presenza di disturbi della conduzione cardiaca nei pazienti affetti da amiloidosi AL 91
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 91
Serum markers of myocardial damage in acute pancreatitis: a prospective time course study 91
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma 91
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 91
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 91
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 91
A practical approach to the diagnosis of systemic amyloidoses 91
IMMUNOENZYMATIC DETECTION OF PROTEINS TRANSFERRED ON NITROCELLULOSE AFTER FIXATION AND STAINING IN POLYACRYLAMIDE GEL 90
Waldenstrom's Macroglobulinemia 90
A focus on recent advances in proteomics - one step closer to entrance into the clinical arena. 90
Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis 90
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin in primary amyloidosis (AL) 90
Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis 90
AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity 90
Totale 10.307
Salva come PNG Salva come JPEG
Categoria #
all - tutte 173.177
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 173.177
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.560 0 0 0 0 0 275 80 414 126 339 264 62
2021/20222.073 28 13 56 25 42 59 34 143 128 72 317 1.156
2022/20236.981 815 460 81 552 667 735 22 375 2.973 38 156 107
2023/20242.324 289 458 101 200 259 538 41 145 21 63 121 88
2024/20256.414 135 574 179 216 112 323 231 398 1.636 231 757 1.622
2025/20268.209 1.203 1.186 1.714 1.880 2.070 156 0 0 0 0 0 0
Totale 36.409